



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE #17

Applicant : Stephen C. Ekker et al.
Serial No. : 09/918,242
Filed : July 30, 2001
Title : INHIBITION OF GENE EXPRESSION USING POLYNUCLEOTIDE ANALOGUES

Art Unit : 1635
Examiner : J. Angell

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL

The following correspondence relating to this application is enclosed for filing:

1. Supplemental Information Disclosure Statement (1 page);
2. Form PTO-1449 (1 page);
3. Copies of Cited References (6);
4. Copy of PCT International Search Report (9 pages); and
5. A Return Postcard.

Please date stamp and return the enclosed postcard by mail.

Please apply any charges or credits to Deposit Account No. 06-1050.

RECEIVED

MAR 26 2003

TECH CENTER 1600/2900

Date: March 18, 2003

Respectfully submitted,

M. Angela Parsons

M. Angela Parsons, Ph.D.
Reg. No. 44,282

Fish & Richardson P.C., P.A.
60 South Sixth Street
Suite 3300
Minneapolis, MN 55402
Telephone: (612) 335-5070
Facsimile: (612) 288-9696

60131694.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

Signature

31803
Trisha J. Anderson

Typed or Printed Name of Person Signing Certificate



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Stephen C. Ekker et al.
Serial No. : 09/918,242
Filed : July 30, 2001
Title : INHIBITION OF GENE EXPRESSION USING POLYNUCLEOTIDE
ANALOGUES

Art Unit : 1635
Examiner : J. Angell

Commissioner for Patents
Washington, D.C. 20231

RECEIVED
MAR 26 2003
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Copies of the references listed on the attached form PTO-1449 are enclosed. A copy of a communication from a foreign patent office in a counterpart application is also enclosed. Please note that the references designated AM through AO, AR, and AS on the attached form PTO-1449 were previously cited in an earlier Information Disclosure Statement, and copies therefore are not provided.

This statement is being filed before the receipt of a first Office Action on the merits. I, the undersigned, hereby certify that each item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application, the communication being dated December 18, 2002, which is not more than three months prior to the filing of this statement.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: March 18, 2003

M. Angela Parsons
M. Angela Parsons, Ph.D.
Reg. No. 44,282

Fish & Richardson P.C., P.A.
60 South Sixth Street, Suite 3300
Minneapolis, MN 55402
Telephone: (612) 335-5070
Facsimile: (612) 288-9696
60131691.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL


I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

Signature

31803
Trisha J. Anderson

Typed or Printed Name of Person Signing Certificate



Substitute (Modified)	PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 09531-033001	Application No. 09/918,242
			Applicant Stephen C. Ekker et al.	
			Filing Date July 30, 2001	Group Art Unit 1635

**Information Disclosure Statement
by Applicant**
(Use several sheets if necessary)

(37 CFR §1.98(b))

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	5,726,059	03/10/98	Wickens et al.			
	AB						
	AC						
	AD						
	AE						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AF	WO 95/31459	11/23/95	PCT				
	AG							
	AH							
	AI							
	AJ							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AK	Dooley and Zon, "Zebrafish: a model system for the study of human disease," <u>Curr. Opin. Genet. Dev.</u> , 2000, 10:252-256
	AL	Giles et al., "Antisense Morpholino Oligonucleotide Analog Induces Missplicing of C-myc mRNA," <u>Antisense & Nucleic Acid Drug Development</u> , 1999, 9:213-220
	AM	Heasman et al., " β -Catenin Signaling Activity Dissected in the Early <i>Xenopus</i> Embryo: A Novel Antisense Approach," <u>Dev. Biol.</u> , 2000, 222:124-134
	AN	Nasevicius and Ekker, "Effective targeted gene 'knockdown' in zebrafish," <u>Nature Genetics</u> , 2000, 26:216-220
	AO	Nasevicius and Ekker, "The zebrafish as a novel system for functional genomics and therapeutic development applications," <u>Curr. Opin. Mol. Ther.</u> , 2001, 3(3):224-228
	AP	Raz et al., " β -Lactamase as a Marker for Gene Expression in Live Zebrafish Embryos," <u>Dev. Biol.</u> , 1998, 203:290-294
	AQ	Stenkamp et al., "Function for <i>Hedgehog</i> Genes in Zebrafish Retinal Development," <u>Dev. Biol.</u> , 2000, 220:238-252
	AR	Summerton and Weller, "Morpholino Antisense Oligomers: Design, Preparation, and Properties," <u>Antisense & Nucleic Acid Drug Development</u> , 1997, 7:187-195
	AS	Summerton, "Morpholino antisense oligomers: the case for RNase H-independent structural type," <u>Biochim. Biophys. Acta</u> , 1999, 1489:141-158

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	